|56.96||-1.50||-2.57%||Vol 692.77K||1Y Perf -28.55%|
|Jan 15th, 2021 16:00 DELAYED|
|- -%||- -|
|Target Price||59.53||Analyst Rating||Moderate Buy 2.36|
|Potential %||4.51||Finscreener Ranking||★★★ 50.93|
|Insiders Trans % 3/6/12 mo.||100/100/-50||Value Ranking||★★ 46.19|
|Insiders Value % 3/6/12 mo.||100/100/-75||Growth Ranking||★★ 45.16|
|Insiders Shares Cnt. % 3/6/12 mo.||100/100/-64||Income Ranking||— -|
|Market Cap||2.92B||Earnings Rating||Neutral|
|Price Range Ratio 52W %||54.17||Earnings Date||18th Feb 2021|
Today's Price Range
5 Year PE Ratio Range
|Moving Averages:||Strong Buy|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||18th Feb 2021|
|Estimated EPS Next Report||0.57|
|EPS Growth Next 5 Years %||13.40|
|Avg. Weekly Volume||765.09K|
|Avg. Monthly Volume||930.53K|
|Avg. Quarterly Volume||905.73K|
NuVasive Inc. (NASDAQ: NUVA) stock closed at 58.46 per share at the end of the most recent trading day (a 4.06% change compared to the prior day closing price) with a volume of 1.01M shares and market capitalization of 2.92B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Medical Devices & Instruments industry, Healthcare sector and employs 2600 people. NuVasive Inc. CEO is .
The one-year performance of NuVasive Inc. stock is -28.55%, while year-to-date (YTD) performance is 3.78%. NUVA stock has a five-year performance of 19.09%. Its 52-week range is between 28.55 and 81, which gives NUVA stock a 52-week price range ratio of 54.17%
NuVasive Inc. currently has a PE ratio of -268.20, a price-to-book (PB) ratio of 3.21, a price-to-sale (PS) ratio of 3.85, a price to cashflow ratio of 15.70, a PEG ratio of 2.32, a ROA of -0.39%, a ROC of 1.64% and a ROE of -0.97%. The company’s profit margin is -5.12%, its EBITDA margin is 17.20%, and its revenue ttm is $758.77 Million , which makes it $14.80 revenue per share.
Of the last four earnings reports from NuVasive Inc., there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.57 for the next earnings report. NuVasive Inc.’s next earnings report date is 18th Feb 2021.
The consensus rating of Wall Street analysts for NuVasive Inc. is Moderate Buy (2.36), with a target price of $59.53, which is +4.51% compared to the current price. The earnings rating for NuVasive Inc. stock is Neutral (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
NuVasive Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
NuVasive Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 35.00, ATR14 : 5.87, CCI20 : 69.33, Chaikin Money Flow : 478.04, MACD : 2.06, Money Flow Index : 56.68, ROC : 6.64, RSI : 62.26, STOCH (14,3) : 95.31, STOCH RSI : 0.41, UO : 85.64, Williams %R : -4.69), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of NuVasive Inc. in the last 12-months were: Gregory T. Lucier (Option Excercise at a value of $0), James Christopher Barry (Option Excercise at a value of $0), Lucas Vitale (Option Excercise at a value of $0), Matthew Link (Option Excercise at a value of $0), Matthew Link (Sold 9 000 shares of value $679 800 ), Nathaniel Sisitsky (Option Excercise at a value of $0), Vickie L. Capps (Buy at a value of $96 460)
Copyright (c) 2021. All rights reserved. Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.com, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
This could take some time, please wait.